New webinar on TTS!
To understand the potential of TTS and learn about the rational development approach by combination of in vitro and in silico methods.
Positive results of the LTS ESKOT trial
The phase I study was conducted in cooperation with Leiden University LUMC and the research group of Prof. Dr. Albert Dahan.
Welcome to our new apprentices
We are proud to offer young people the opportunity to start their careers in a wide range of apprenticeships.
LTS CEO, Bas van Buijtenen, reveals his formula for developing stronger patient engagement and greater outcomes for all.
While injections may achieve the desired therapeutic effect, parenteral administration can compare unfavourably with alternative methods of delivery in many aspects. We Care. We Create. We Deliver. All our endeavours are focused on at least one of three core challenges: being patient empowerment; affordability and connectivity.
EsoCap and LTS announce major milestone achievement in their cooperation
LTS and EsoCap AG are pleased to announce completion of manufacture of the CTS (Clinical Trial Samples) for the ACESO clinical study conducted by EsoCap.
Ways in which we can help you manage anxiety levels in the development of your mental disorder therapies.
One focus area for new therapeutic opportunities is in mental disorders. The topic of mental health has spent an increasing amount of time in the spotlight over the past year, given the levels of anxiety and stress so many have been forced to endure.
LTS and Revive Therapeutics enter into Feasibility Agreement to develop Oral Psilocybin Thin Film Strip
LTS and Revive Therapeutics Ltd. are pleased to announce that they have entered into a feasibility agreement to develop and manufacture a proprietary oral psilocybin thin film strip for the Company’s clinical and commercial initiatives to evaluate in mental illness, neurological and substance abuse disorders.
How we are mitigating the perceived challenges surrounding MAPs.
We believe that if the API can be delivered in an injection, it can probably be delivered in a MAP. We also believe that the clear potential in MAPs, which has been untapped to date, is now ready to be realised using the LTS technology platform.
LTS is now member of the „VEA-Initiative Klimafreundlicher Mittelstand“
The members of the initiative bear responsibility for their employees, for the environment and for future generations.
LTS receives notice of allowance for U.S. patent related to Asenapine patch
The United States Patent and Trademark Office has issued the notice of allowance for its U.S. Patent Application entitled "Transdermal Therapeutic System Containing Asenapine“.